14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.492 4 days ( 0.341 % )
Last Price $14.62 -0.341 %
High/ Low $14.57 - $14.84 1.27%
Chg 7 Days -0.679 % $14.72 $14.62
Chg 30 Days -4.44 % $15.30 $14.62
Chg 12 mos 0.689 % $14.52 $14.62
Trend - 3 mos -0.191 % Width: 21.88 %
Trend - 12 mos 11.68 % Width: 59.99 %
Pred. range - 3 mos $14.20 - $17.31 -2.87 % - 18.38 %
Pred. range - 12 mos $12.31 - $19.69 -15.81 % - 34.68 %
Short MA avg 3 mos Buy Apr 22, 2024 - 3 days
Long MA avg 3 mos Buy Mar 19, 2024 - 26 days
Short/Long MA avg 3 mos Sell Mar 19, 2024 - 26 days
Short MA avg 12 mos Sell Apr 11, 2024 - 10 days
Long MA avg 12 mos Sell Apr 11, 2024 - 10 days
Short/Long MA avg 12 mos Sell Apr 18, 2024 - 5 days
Pivot Short Buy Apr 18, 2024 - 5 days
Bollinger Buy Apr 18, 2024 - 5 days
MACD Sell No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Deciphera Pharmaceuticals Inc

Deciphera Pharmaceuticals Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. Th... DCPH Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT